ATE553112T1 - Ttk in der diagnose und als therapeutisches target bei krebs - Google Patents

Ttk in der diagnose und als therapeutisches target bei krebs

Info

Publication number
ATE553112T1
ATE553112T1 AT02709637T AT02709637T ATE553112T1 AT E553112 T1 ATE553112 T1 AT E553112T1 AT 02709637 T AT02709637 T AT 02709637T AT 02709637 T AT02709637 T AT 02709637T AT E553112 T1 ATE553112 T1 AT E553112T1
Authority
AT
Austria
Prior art keywords
ttk
methods
genes
cancer
diagnosis
Prior art date
Application number
AT02709637T
Other languages
English (en)
Inventor
Christoph Reinhard
Anne Jefferson
Vivien Chan
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE553112T1 publication Critical patent/ATE553112T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037Protein kinase (2.7.1.37)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT02709637T 2001-02-21 2002-02-21 Ttk in der diagnose und als therapeutisches target bei krebs ATE553112T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27125401P 2001-02-21 2001-02-21
PCT/US2002/005278 WO2002068444A1 (en) 2001-02-21 2002-02-21 Ttk in diagnosis and as a therapeutic target in cancer

Publications (1)

Publication Number Publication Date
ATE553112T1 true ATE553112T1 (de) 2012-04-15

Family

ID=23034823

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02709637T ATE553112T1 (de) 2001-02-21 2002-02-21 Ttk in der diagnose und als therapeutisches target bei krebs

Country Status (9)

Country Link
EP (1) EP1377596B1 (de)
JP (2) JP4429604B2 (de)
KR (1) KR100876327B1 (de)
CN (2) CN100578227C (de)
AT (1) ATE553112T1 (de)
AU (1) AU2002244112B2 (de)
CA (1) CA2438092C (de)
NZ (1) NZ527421A (de)
WO (1) WO2002068444A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474844A1 (en) * 2002-02-12 2003-08-21 Chiron Corporation Cks1 inhibitors
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
AU2003297318A1 (en) * 2002-12-20 2004-07-22 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
JP4721903B2 (ja) * 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
CN102747140A (zh) * 2004-12-08 2012-10-24 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
ES2364670T3 (es) * 2005-02-25 2011-09-12 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos ttk.
JP4647456B2 (ja) * 2005-10-11 2011-03-09 オンコセラピー・サイエンス株式会社 新規基質を用いたttk活性抑制剤のスクリーニング方法
AU2006337085B2 (en) * 2005-12-27 2013-12-19 Curis, Inc. Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders
EP2102360A2 (de) * 2006-12-13 2009-09-23 Oncotherapy Science, Inc. Ttk als tumormarker und therapeutisches ziel für lungenkrebs
US8492356B2 (en) 2007-12-21 2013-07-23 University Health Network Methods of inhibiting tumor growth using TTK antagonists
WO2010007756A1 (ja) * 2008-07-14 2010-01-21 塩野義製薬株式会社 Ttk阻害作用を有するピリジン誘導体
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
CA2822491C (en) * 2011-01-21 2023-02-14 Basilea Pharmaceutica Ag Bubr1 as a biomarker for furazanobenzimidazoles
PL3484888T3 (pl) 2016-07-18 2023-06-26 University Health Network Stałe postacie inhibitora TTK
CN117065023B (zh) * 2023-06-16 2025-11-21 华中科技大学同济医学院附属协和医院 Ttk基因及ttk抑制剂在治疗血管损伤后再狭窄中的功能及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586581B1 (en) * 1999-03-23 2003-07-01 The Mt. Sinai School Of Medicine Of New York University Prolactin regulatory element binding protein and uses thereof
AU1339701A (en) * 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets

Also Published As

Publication number Publication date
AU2002244112B2 (en) 2007-05-10
NZ527421A (en) 2005-05-27
EP1377596B1 (de) 2012-04-11
WO2002068444A1 (en) 2002-09-06
JP2004526716A (ja) 2004-09-02
CA2438092C (en) 2011-08-09
EP1377596A4 (de) 2005-07-13
KR100876327B1 (ko) 2008-12-31
CN101732717A (zh) 2010-06-16
JP4838835B2 (ja) 2011-12-14
JP4429604B2 (ja) 2010-03-10
EP1377596A1 (de) 2004-01-07
JP2009143890A (ja) 2009-07-02
CN1492875A (zh) 2004-04-28
KR20030076695A (ko) 2003-09-26
CN100578227C (zh) 2010-01-06
CA2438092A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
ATE553112T1 (de) Ttk in der diagnose und als therapeutisches target bei krebs
Pirsaheb et al. Current advances of carbon dots based biosensors for tumor marker detection, cancer cells analysis and bioimaging
Verdoes et al. Improved quenched fluorescent probe for imaging of cysteine cathepsin activity
EP4282405A3 (de) Nachweis von krebs-biomarkern mittels nanopartikeln
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DE602006015966D1 (de) Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
WO2003070979A3 (en) Materials and methods relating to cancer diagnosis
WO2023004079A3 (en) Compositions and methods for detection of liver cancer
WO2017217807A3 (ko) Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물
BRPI0412110A (pt) genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
WO2003083102A3 (en) Cancer associated protein phosphatases and their uses
CY1115258T1 (el) Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων
Que et al. New strategy for antimetastatic treatment of lung cancer: a hypothesis based on circulating tumour cells
Ma et al. Pan-cancer analysis of ADAMs: A promising biomarker for prognosis and response to chemotherapy and immunotherapy
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
BRPI0608429A2 (pt) método e kit para prognóstico ou avaliação da eficácia do tratamento de um tumor sólido em um paciente de interesse; e método para a identificação de marcadores que sejam prognósticos de um tumor sólido
WO2006065940A3 (en) Identification and use of prognostic and predictive markers in cancer treatment
WO2003076651A3 (en) Cancer associated araf1 protein kinase and its uses
Kundranda et al. Role of ctDNA in the Management of Gallbladder Cancer
Cherciu et al. Targeted Confocal Laser Endomicroscopy (CLE) for the Assessment of Putative Cancer Stem Cell Markers in Colorectal cancer-A Pilot Study